The IL-1β Antibody Gevokizumab Limits Cardiac Remodeling and Coronary Dysfunction in Rats With Heart Failure.

Abstract

This study reports preclinical data showing that the interleukin (IL)-1β modulation is a new promising target in the pathophysiological context of heart failure. Indeed, in nondiabetic Wistar and diabetic Goto-Kakizaki rats with chronic heart failure induced by myocardial infarction, administration of the IL-1β antibody gevokizumab improves 'surrogate' markers of survival (i.e., left ventricular remodeling, hemodynamics, and function as well as coronary function). However, whether IL-1β modulation per se or in combination with standard treatments of heart failure improves long-term outcome in human heart failure remains to be determined.

• Authors: Najah Harouki, Lionel Nicol, Isabelle Remy-Jouet, Jean-Paul Henry, Anais Dumesnil, Annie Lejeune, Sylvanie Renet, Francesca Golding, Zoubir Djerada, Didier Wecker, Virginie Bolduc, Muriel Bouly, Jerome Roussel, Vincent Richard, Paul Mulder
• Journal: JACC. Basic to translational science (JACC Basic Transl Sci) Vol. 2 Issue 4 Pg. 418-430 (Aug 2017) ISSN: 2452-302X [Electronic] United States
• PMID: 30062160 (Publication Type: Journal Article)